IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--IVERIC announced the first patient has been dosed in GATHER2, the second Phase 3 clinical trial for Zimura in patients with GA secondary to AMD.